Catalent's ADVASEPT Technology

Article

Pharmaceutical Technology Europe

Catalent’s ADVASEPT™ Technology is an advanced aseptic filling solution that reduces and even eliminates the main concerns associated with traditional glass vials, while reducing breakage risks and container weight for transportation and disposal.

 

Catalent’s ADVASEPT™ Technology is an advanced aseptic filling solution for clinical or commercial supply demands of biologics, parenteral, respiratory, and other products.


Catalent is able to leverage a superior manufacturing process that is rooted in the principles of Quality by Design to drastically reduce the risk of contamination by minimizing variables, eliminating human intervention and reducing the required class A space.  The technology provides an automated container formation and closed filling process that delivers a more efficient, secure and robust injectable solution for your product.


The process  utilises Blow-Fill-Seal manufacturing to produce a glass-free primary packaging container that reduces, and even eliminates, the main concerns associated with traditional glass vials, such as contamination with foreign or glass particulates and surface delamination. The ultrapure plastic design reduces breakage risks and container weight for transportation and disposal, as well as protein surface interactions. The technology is flexible, to accommodate a variety of product volumes, and can be designed to minimise headspace within the vial, reducing agitation of drug products in transit.


Catalent continues to develop and evolve ADVASEPT technology to increase the safe handling of parenteral drug products, by incorporating an optional needle-free luer lock connection fitting to containers.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content